Screener
Royalty Pharma RPRX Balance Sheet Statement
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| $811.99M+28.5% | $586.4M-46.1% | $618.7M-33.4% | $938.94M-1.2% | $631.91M-64.2% | ||
| $25M+89.4% | $21.9M+81.0% | $18.8M-67.7% | $16.1M-66.8% | $13.2M-65.7% | ||
| $20.12B+3.5% | $20.04B+3.3% | $20.46B+2,511% | $20.09B+3.8% | $19.44B+5.0% | ||
| $1.76B+16.1% | $1.43B-22.6% | $1.53B-15.2% | $1.85B+3.1% | $1.52B-41.1% | ||
| $923.54M-0.1% | $924.63M— | $924.63M— | $924.63M— | $924.63M— | ||
| $241.92M+119% | $173.27M+22.8% | $171.31M-8.4% | $129.39M-43.5% | $110.53M-37.9% | ||
| $19.82B+8.2% | $19.82B+12.5% | $19.62B+7.7% | $19.35B+7.2% | $18.32B+3.8% | ||
| $35.57M+76.0% | $25.48M-32.3% | $19.4M+45.1% | $41.42M+87.8% | $20.21M-13.7% | ||
| $380M-62.0% | $380M-61.9% | $380M-61.9% | $380M-61.9% | $999.44M— | ||
| $630.93M-47.7% | $535.68M-54.7% | $636.21M-49.2% | $530.8M-54.5% | $1.21B+338% | ||
| $8.58B+22.5% | $8.58B+29.6% | $8.57B+29.6% | $8.57B+29.6% | $7B-7.9% | ||
| $10.03B+13.8% | $9.88B+26.3% | $9.91B+25.7% | $9.73B+25.0% | $8.82B+11.6% | ||
| $2.46B+10.6% | $2.51B+1.1% | $2.36B-17.2% | $2.3B-16.7% | $2.22B-6.5% | ||
| $9.79B+3.1% | $9.94B+1.6% | $9.71B-6.1% | $9.62B-6.2% | $9.49B-2.6% | ||
| $19.82B+8.2% | $19.82B+12.5% | $19.62B+7.7% | $19.35B+7.2% | $18.32B+3.8% |
FAQ
- What are Royalty Pharma's total assets?
- Royalty Pharma (RPRX) holds $19.8B in total assets, up 8.2% year over year.
- How much debt does Royalty Pharma have?
- Royalty Pharma carries $9.0B in total debt against $9.8B of shareholders' equity, a debt-to-equity ratio of 0.92.
- How much cash does Royalty Pharma have?
- Royalty Pharma holds $812.0M in cash and equivalents.
- Can Royalty Pharma cover its short-term obligations?
- Its current ratio is 2.80 — current assets exceed current liabilities.
- Where does Royalty Pharma's balance sheet data come from?
- Every line is extracted from Royalty Pharma's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
